X4 Pharmaceuticals Inc Dr. Ragan Discusses X4's Work To Advance Disease-Modifying Therapies For Rare Genetic Diseases Transcript
Welcome to TrialSite News Podcast Series. Today, we are speaking with Dr. Paula Ragan, CEO of X4. Now X4 is currently developing therapies for rare genetic diseases that result from dysfunction of the immune system and is currently undergoing a global Phase 3 trial for WHIM syndrome in two Phase 1b trials for Waldenström macroglobulinemia, a type of rare lymphoma and a severe congenital neutropenia.
So doctor, welcome.
Thank you so much. Appreciate the chance to speak to you and your audience.
Questions & Answers
Pleasure is ours. Now you made the leap to found X4 Pharmaceuticals a few years ago. What were the drivers to found this company?
For me it's all about the patients. I really am excited to figure out how to provide my gifts to people who have remaining unmet needs and kind of are under champion in
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |